

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization

International Bureau

(43) International Publication Date
06 February 2020 (06.02.2020)



(10) International Publication Number
WO 2020/028647 A1

(51) International Patent Classification:

C07K 16/28 (2006.01) C07K 14/725 (2006.01)
A61K 35/17 (2015.01) G01N 33/50 (2006.01)
A61K 39/00 (2006.01)

(21) International Application Number:

PCT/US2019/044638

(22) International Filing Date:

01 August 2019 (01.08.2019)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

62/713,994 02 August 2018 (02.08.2018) US
62/756,391 06 November 2018 (06.11.2018) US

(71) Applicant: **KITE PHARMA, INC** [US/US]; 2400 Broad-
way, Santa Monica, California 90404 (US).

(72) Inventors: **ROSSI, John M.**; c/o Kite Pharma, Inc., 2400
Broadway, Santa Monica, California 90404 (US). **BOT,**
Adrian L.; c/o Kite Pharma, Inc., 2400 Broadway, Santa
Monica, California 90404 (US).

(74) Agent: **WU, Henry** et al.; Kite Pharma, Inc., 2400 Broad-
way, Santa Monica, California 90404 (US).


(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,

AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO,
DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN,
HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP,
KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME,
MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ,
OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA,
SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN,
TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, GH,

GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ,
UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ,
TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK,
EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV,
MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM,
TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW,
KM, ML, MR, NE, SN, TD, TG).

(54) Title: CHIMERIC ANTIGEN RECEPTOR THERAPY T CELL EXPANSION KINETICS AND USES THEREOF



DT, doubling time; ORR, objective response rate; Q, quartile.
Interrupted line: 95% confidence interval

FIG. 1A




FIG. 1B

(57) Abstract: The disclosure provides methods of treating a malignancy comprising administering an effective dose of a chimeric antigen receptor genetically modified T cell immunotherapy and methods for manufacturing such immunotherapy. Some aspects of the disclosure relate to methods of determining objective response of a patient to a T cell immunotherapy based on the levels of attributes prior to administration to the patient.

WO 2020/028647 A1

[Continued on next page]

Declarations under Rule 4.17:

- *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*
- *as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))*

Published:

- *with international search report (Art. 21(3))*
- *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*
- *with sequence listing part of description (Rule 5.2(a))*